Bessemer Group
MCRB icon

Bessemer Group’s Seres Therapeutics MCRB Stock Holding History

Bessemer Group’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7
Closed -$1K – 1972
2022
Q1 		$1K Hold
7
– – ﹤0.01% 1779
2021
Q4 		$1K Hold
7
– – ﹤0.01% 1814
2021
Q3 		$1K Hold
7
– – ﹤0.01% 1630
2021
Q2 		$3K Hold
7
– – ﹤0.01% 1482
2021
Q1 		$3K Buy
+7
New +$3.22K ﹤0.01% 1439

Other funds holding MCRB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

Bessemer Group's MCRB Position: Q2 2022 in Review

Bessemer Group sold out of Seres Therapeutics (MCRB) in Q2 2022, closing a stake of 7 shares — an estimated $1K sold.

Bessemer Group first reported a position in MCRB in Q1 2021 and held it in 5 quarters. The position peaked at $3K in Q2 2021. 123 funds tracked by Wall St. Rank hold MCRB as of Q2 2022.

  • Bessemer Group reported no remaining Seres Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Bessemer Group sold 7 Seres Therapeutics shares in Q2 2022, an estimated $1K.
  • Bessemer Group first reported a position in Seres Therapeutics in Q1 2021 and held it in 5 quarters.
  • Bessemer Group's Seres Therapeutics position peaked at $3K in Q2 2021.
  • 123 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2022.

Based on Bessemer Group's 13F filing for Q2 2022, filed 10 Aug 2022.